Voice News BD

Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billion deal

Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billi

Covered by 1 source ·

Every side

  • Reuters
    high factuality Thomson Reuters Corp · corporate

    Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billi

    Read original →

← All stories on Voice News BD